Meningococcal Disease: Recommended vaccinations
Back to search
Export to spreadsheet
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 		 Vaccination not funded by the National Health system
 		 Mandatory vaccination
MonthsYears
234568111213141521011121314151617181924≥ 25
Austria
MenB1
MenB1
MenB1
Men C - Men B
MCV4
Belgium
MCV4
MCV4
Bulgaria
Croatia
Cyprus
MenC
MPSV42
Czech Republic
MenB3
MenB4
MCV4/MenB5
MCV4/MenB3
Denmark
Estonia
Finland
France
MenB6
MenB - MenC7
MenB - MenC8
MenC9
Germany
MenC
MenC
Greece
MCV4/MenB
MenC
MenC
MCV4
MCV4
MCV4/MenB
Hungary
MenC
MenC
MenC10
Iceland
MenC
MenC
Ireland
MenB
MenB
MenC
MenB
MenC11
MCV4
Italy
MenB12
MenB12
MenB12
MenB12
MenC13
MCV413
Latvia
Liechtenstein
MenC14
MenC15
Lithuania
MenB
MenB
MenB16
Luxembourg
MenB17
MenC
MenB18
MenC19
MenB18
Malta
MenB
MCV4
MenB
MenB
MCV4
MCV4
Netherlands
MCV420
MCV421
Norway
Poland
MenC
MenC
Portugal
MenB
MenB
MenB - MenC
Romania
Slovakia
Slovenia
Spain
MenB22
MenB - MenC22
MenB - MenC22
MCV423
MCV424
Sweden

Footnotes:

  1. Please refer to official recommendations for timing and number of doses required according to age. For infants, 3 doses from 3 months of age with at least one month interval - Booster between 13-15 months.
  2. vaccines only given on specific indications
  3. 1. Vaccination with MenB vaccine and MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination is covered by health insurance for small infants since May 2020 for MenB vaccine if vaccination is started before the age of six months and for MCV4 vaccine if vaccination is given as a single dose in the second year of life. 3. In September 2021, the inclusion of vaccinations with MCV4 and MenB vaccine for adolescents in addition to small infants as covered by health insurance was newly approved; from January 2022, an amendment to the law is to enter into force and vaccinations are to be paid for: a. MenB vaccine if it is started before the age of 12 months or from the completion of the fourteenth to the completion of the fifteenth year of the age; b. MCV4 vaccine if it is made in a single dose from the completion of the first to the completion of the second year of age or from the completion of the fourteenth to the completion of the fifteenth year of the age. Recommendation (Czech, English) http://www.szu.cz/ockovani-proti-meningokokovym-onemocnenim
  4. 2nd dose.
  5. 3rd dose of MenB. 1. Vaccination with MenB vaccine and MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination is covered by health insurance for small infants since May 2020 for MenB vaccine if vaccination is started before the age of six months and for MCV4 vaccine if vaccination is given as a single dose in the second year of life. 3. In September 2021, the inclusion of vaccinations with MCV4 and MenB vaccine for adolescents in addition to small infants as covered by health insurance was newly approved; from January 2022, an amendment to the law is to enter into force and vaccinations are to be paid for: a. MenB vaccine if it is started before the age of 12 months or from the completion of the fourteenth to the completion of the fifteenth year of the age; b. MCV4 vaccine if it is made in a single dose from the completion of the first to the completion of the second year of age or from the completion of the fourteenth to the completion of the fifteenth year of the age. Recommendation (Czech, English) http://www.szu.cz/ockovani-proti-meningokokovym-onemocnenim
  6. Vaccination introduced in 2022.
  7. Men B introduced in 2022. Not mandatory.
  8. Men B is not mandatory.
  9. 1 dose until 24 years
  10. The meningococcal C vaccine has been available on a voluntary base with 70% reimbursement for years, however, since January 1st, 2017, it is offered to all children aged under 2 years with 100% reimbursement, still on a voluntary-based approach.
  11. Hib/MenC combined vaccine
  12. Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
  13. Meningococcal C vaccination, one dose for children between 13-15 months. Meningococcal ACWY, one dose for adolescents age 12-14
  14. not part of the basic vaccination plan. catch-up possible until 5 years of age
  15. not part of the basic vaccination plan. catch-up possible until 20 years of age
  16. Can be administered concomitantly with MMR
  17. Two/three doses recommended in at-risk groups, depending on age. Further information available at: https://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite.html
  18. Two/three doses recommended in at-risk groups, depending on age. Further information available at: http://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite/2018-avis-vaccination-meningocoque-groupe-b.pdf
  19. see https://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite.html
  20. Replaced MenC in 2018.
  21. Introduced in 2018
  22. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
  23. One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
  24. The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/adolescentes-meningo/home.htm